Table 1. Patient characteristics.
| Patient characteristics at enrollment | Overall (n=1188) | Vital status as of end of 2007 | |
|---|---|---|---|
| Alive (n=895) | Dead (n=293) | ||
| Age groups, n (%) | |||
| - 25-34 years | 226 (19.0) | 162 (18.1) | 64 (21.8) |
| - 35-44 years | 538 (45.3) | 404 (45.1) | 134 (45.7) |
| - 45-54 years | 337 (28.4) | 269 (30.1) | 68 (23.2) |
| - 55-64 years | 87 (7.3) | 60 (6.7) | 27 (9.2) |
| Sex, n (%) | |||
| - male | 905 (76.2) | 697 (77.9) | 208 (71.0) |
| - female | 283 (23.8) | 198 (22.1) | 85 (29.0) |
| Race/Ethnicity, n (%) | |||
| - White, non-Hispanic | 462 (38.9) | 357 (39.9) | 105 (35.8) |
| - Black, non-Hispanic | 492 (41.4) | 352 (49.3) | 140 (47.8) |
| - Hispanic | 195 (16.4) | 156 (17.4) | 39 (13.3) |
| - Other | 39 (3.3) | 30 (3.4) | 9 (3.0) |
| Time since AIDS diagnosis | |||
| - ≤ 1 year before enrollment into LSOCA (incident AIDS) | 456 (38.4) | 368 (41.1) | 88 (30.0) |
| - > 1 year before enrollment into LSOCA (prevalent AIDS) | 732 (61.6) | 527 (58.9) | 205 (70.0) |
| Reason for AIDS diagnosis# | |||
| - Clinical diagnosis | 429 (37.7) | 312 (36.6) | 117 (40.9) |
| - CD 4 count < 200 cells/μL | 710 (62.3) | 541 (63.4) | 169 (59.1) |
| HIV-exposure category, n (%) | |||
| - Men having sex with men | 495 (41.7) | 390 (43.6) | 105 (35.8) |
| - Injection drug use | 86 (7.2) | 60 (6.7) | 26 (8.9) |
| - Other | 607 (51.1) | 445 (49.7) | 162 (55.3) |
| CD 4 T-cell count (cells/μL) | |||
| - < 200 | 687 (57.8) | 455 (50.8) | 232 (79.2) |
| - 200-499 | 375 (31.6) | 330 (36.9) | 45 (15.4) |
| - ≥ 500 | 126 (10.6) | 110 (12.3) | 16 (5.5) |
| Nadir T-cell CD 4 count (cells/μL) | |||
| - < 100 | 905 (76.2) | 655 (73.2) | 250 (85.3) |
| - ≥ 100 | 283 (23.8) | 240 (26.8) | 43 (14.7) |
| HIV viral load at enrollment (copies/mL) | |||
| - < 400 | 501 (42.2) | 451 (50.4) | 50 (17.1) |
| Cytomegalovirus retinitis, n (%) | 233 (19.6) | 156 (17.5) | 77 (26.3) |
| HAART treatment, n (%) | 968 (81.6) | 763 (85.4) | 205 (70.0) |
#
Available for 1139 patients